Is neuromelanin the imaging biomarker for the early diagnosis of Parkinson\u27s disease that we were looking for? by Pavese N
Is Neuromelanin the imaging biomarker for the early diagnosis of 
Parkinson’s disease that we were looking for? 
Nicola Pavese MD, PhD, FRCP1,,2 
 
1. Institute of Neuroscience. Faculty of Medical Sciences, Newcastle 
University, UK 
2. Department of Nuclear Medicine and PET Centre, Aarhus University 
Hospital, Nørrebrogade 44, 8000, Aarhus, Denmark 
 
 
 
Correspondence to: 
Professor Nicola Pavese, MD, PhD, FRCP 
Newcastle Magnetic Resonance Centre & 
Positron Emission Tomography Centre 
Newcastle University 
Campus for Ageing & Vitality 
Westgate Road 
Newcastle upon Tyne NE4 5PL 
Tel: 0191 2081264 
Fax: 0191 2081251 
Neuromelanin is a granular dark pigment that is normally found in the 
human brain in the dopaminergic neurons of the substantia nigra pars 
compacta (SNc) and noradrenergic neurons of the locus coeruleus (LC).  It 
is thought to result from the autooxidation process of dopamine 
derivatives in these neurons, although other alternative mechanisms have 
been proposed [1]. 
While in healthy brain neuromelanin concentration in the SNc and LC 
neurons increases over time [2], numerous neuropathological studies have 
demonstrated that the content of this pigment in these regions is reduced 
in neurodegenerative diseases, such as Parkinson's disease (PD) and other 
parkinsonian syndromes characterised by nigral neuronal loss [1,3]. 
Additionally, in patients with PD, the concentration of neuromelanin in the 
SNc appears to further decrease with disease progression [1]. Therefore, in 
recent years, there has been a growing interest in developing novel 
imaging techniques to enable the in vivo assessment of brain neuromelanin 
content with the hope that this could serve as a robust imaging biomarker 
to improve the early diagnosis of PD and possibly to allow longitudinal 
assessments of disease progression.   
Since neuromelanin exhibits paramagnetic properties when combined 
with metals such as copper and iron, neuromelanin containing regions are 
detected as distinct high-intensity areas on MRI T1-weighted fast spin-
echo sequences acquired at high magnetic fields. These neuromelanin 
sensitive MRI sequences are easily implemented also on 3 Tesla MRI 
scanners and, therefore, in the last ten years, neuromelanin-sensitive MRI 
(NM-MRI) has been increasingly employed to assess patients with PD in 
several research centres worldwide. The published studies have reliably 
demonstrated significant reductions in the neuromelanin-related signal in 
the SNc of PD brains, providing high diagnostic accuracy for differentiating 
PD patients from healthy controls [4]. Furthermore, NM-MRI could also be 
potentially useful in the differentiation of idiopathic PD from Essential 
Tremor (ET), as well as other types of Parkinsonism. However, there have 
been only a few studies performed in patients with atypical Parkinsonism, 
which have demonstrated conflicting results [4], and only one study has 
compared PD with ET patients [5]. 
 
In the clinical setting, differentiating between PD, especially tremor-
dominant PD (PDT), and ET can be particularly challenging in early stages 
of disease, even in specialist Movement Disorder Clinics.  One clinical study 
has reported that one-third of patients who received an initial diagnosis of 
ET were misdiagnosed, with PD being the most common final diagnosis 
[6]. Several factors can explain this diagnostic uncertainty. PDT patients 
often have very mild or absent bradykinesia and rigidity, and a recent 
investigation of the clinical characteristics of a large cohort of recently 
diagnosed PD cases with abnormal DaTSCAN has shown that over 20% of 
patients presenting with tremor did not exhibit resting tremor [7].  
To make matters more complicated, about 18% of ET patients, especially 
those with long disease duration, experience tremor at rest, and 
bradykinesia and rigidity can also be detected in these patients [8].  
Additionally, a community-based study has shown that patients with ET 
had a fourfold to fivefold increased risk of developing PD compared with 
controls over a 3.3-year follow-up, suggesting that patients with long-
standing ET might have co-occurrence of the two diseases [9]. 
The advent of a commercially available SPECT ligand ([123I]‐FP‐CIT, 
DaTSCAN) to visualize dopamine transporter function in the striatum has 
increased our diagnostic accuracy in patients with an uncertain diagnosis. 
[123I]‐FP‐CIT SPECT imaging has been reported to have 97% sensitivity for 
the clinical diagnosis of Parkinsonism and 100% specificity for ET [10].  
However, [123I]‐FP‐CIT SPECT has a number of limitations. It is still not 
available worldwide and there are risks associated to the exposure to 
ionising radiation. Additionally, it has low specificity and sensitivity to 
differentiate PD from atypical parkinsonian syndromes, such as multiple 
system atrophy and progressive supranuclear palsy [11], and it is still 
debated if it is a suitable surrogate marker of disease progression [12]. 
NM-RMI could overcome all these limitations and this explains why this 
technique has recently raised so much interest in both research and 
clinical settings. 
 
 Wang and colleagues [13] used NM-MRI to assess whether PDT patients 
and patients with ET have different patterns of neuromelanin content in 
the SNc compared with age-matched controls and whether this could be 
useful in differentiating these two conditions early is the disease process.  
Importantly, both groups of patients were untreated, thus eliminating the 
risk of potential confounding effects of medications on the MRI findings. 
Another strength of the study is that the authors performed both 
quantitative measurements (SNc width and contrast-to-noise ratio, CNR) 
and visual analysis of the SNc high signal intensity on NM-MRI images. 
Receiver Operating Characteristic (ROC) analysis and the more sensitive 
Net Reclassification Improvement (NRI) were then used to investigate 
which NM-MRI parameters better discriminated the PDT group from the 
ET group. 
In line with previous published studies [4], three different SNc sub-regions 
(lateral, central and medial) were identified.  Compared with age-matched 
controls and the ET patients, PDT patients, as a group, were found to have 
a significant decrease in the width and in the contrast-to-noise ratio (CNR) 
values of the lateral and central sub-regions of the SNc.  Similarly, when 
using the visual approach, the total visual score of all SNc sub-regions was 
significantly reduced in PDT compared with controls, but this was not the 
case in the ET group.  
The best differentiation between ET and PDT was achieved with the width 
of the lateral sub-region SNc. However, a good diagnostic value was also 
achieved with visual analysis alone. In fact, NRI analysis indicated that 
visual analysis and the width of the lateral SNc sub-region had similar 
diagnostic power. 
The sample size of this study is relatively small with approximately 20 
patients included in each group. Additionally, the analysis of individual 
patients was not performed and it is, therefore, unclear if this technique is 
able to identify patients with an abnormal SNc neuromelanin pattern at an 
individual level. Nevertheless, if confirmed in larger cohorts of patients, the 
results of this study are very promising, as they suggest that patients with 
ET and PDT can be differentiated on the basis of their SNc neuromelanin 
pattern on NM-MRI imaging.  Moreover, it appears that a simple visual 
analysis of NM-MRI images is nearly as good as the quantitative measures 
to provide high diagnostic accuracy for distinguishing ET from the PDT 
subtype, making it a relatively simple tool to be used in clinical practice.  
It has to be acknowledged that this is not the first NM-MRI study to 
compare SNc neuromelanin patterns in patients with PD and ET. Reimao 
and colleagues [5] have previously reported that, compared with age-
matched healthy controls, PD patients, but not ET patients, had marked 
decreases in the area and width of the T1 high signal in the SN region, 
particularly in its ventrolateral segment.  However, the study by Wang and 
colleagues is the first to compare ET patients with PD patients with a 
tremor-predominant phenotype who in the clinical setting pose the most 
difficult diagnostic challenge in the early stages of disease often leading to 
misdiagnosis.  
One possible weakness of this study is that patients were enrolled in the 
study based on their current clinical diagnosis and there was no gold 
standard for the final diagnosis.  Therefore, there is a potential risk of 
misdiagnosis. If performed in these patients, molecular imaging of the 
striatal pre-synaptic dopaminergic function would have strengthened the 
clinical diagnostic accuracy of these patients and could have been an 
appropriate comparator to assess the diagnostic value of NM-MRI.  Further 
studies are requested to address this issue. However, when compared with 
data available in the medical literature, NM-MRI seems to have slightly 
lower diagnostic sensitivity and specificity than DaTSCAN [10] to 
differentiate PD from ET (NM-MRI: sensitivity and specificity 90.5% and 
83.3%, respectively, when the cutoff value for the width of lateral sub-
region was set as 0.525 mm; DaTSCAN overall sensitivity and specificity of 
96%), but slightly higher than transcranial sonography (sensitivity and 
specificity 78% and 85% respectively) [14].  Transcranial sonography has 
the further limitation that 10% of people have no temporal bone window 
and, therefore, the examination cannot be carried out. Additionally, the 
typical midbrain hyperechogenicity observed in PD patients does not 
change with disease progression, and therefore cannot be used as a marker 
of disease progression. 
 
 In conclusion, the study by Wang and colleagues [13] adds further weight 
to the view that NM-MRI could provide a reliable imaging biomarker of 
nigral pathology/abnormalities in PD. This could not only be potentially 
useful to differentiate PD from ET, but also in distinguishing PD from other 
Parkinsonian syndromes. However, it should be acknowledged that further 
investigations are required in the field. In particular NM-MRI should be 
tested in large longitudinal cohorts of patients. It is quite surprising that so 
far only small cohorts of patients have been published, despite NM-MRI 
having been available in a number of centres for more than a decade.  It is 
also essential to reach expert consensus on technical guidelines for the use 
of NM-MRI as diagnostic and progression markers in PD, including 
technical standards, imaging protocols, and methods of analysis.  This will 
allow multi-center data collection and lead to a better validation of NM-
MRI as an effective marker of dopamine cell loss in PD and related 
disorders.  
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